Equities

Feedback PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Feedback PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)10.80
  • Today's Change-0.35 / -3.14%
  • Shares traded430.00
  • 1 Year change-43.90%
  • Beta0.4752
Data delayed at least 20 minutes, as of Feb 10 2026 08:58 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Feedback plc is a United Kingdom-based clinical infrastructure specialist. The Company designs products that enhance clinician access to patient data and to their colleagues. The Company's approach centers around individual patient episodes, into which it pulls relevant clinical data from hospital systems and around which it builds remote clinical teams for collaboration. The Company’s segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa and CareLocker. Bleepa is its application layer and sits on top of CareLocker as its data layer. Bleepa is its communication and collaboration platform that displays clinical results at a certified and regulated quality, which enables multidisciplinary team working and diagnostic-enhanced advice and guidance. CareLocker is its patient-facing platform that gives patients access and control over their diagnostic and other clinical data.

  • Revenue in GBP (TTM)885.62k
  • Net income in GBP-7.32m
  • Incorporated1958
  • Employees28.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Image Scan Holdings Plc1.62m-288.02k1.92m13.00--1.34--1.18-0.0021-0.00210.01180.01050.64591.752.43---11.500.0905-17.470.135858.5052.65-17.800.09171.85--0.06160.00-43.45-14.23-239.13--34.92--
Genincode PLC2.91m-4.97m3.30m36.00--1.24--1.13-0.0232-0.02320.01370.00930.656215.742.8780,944.45-111.87---164.53--53.02---170.49--2.73-10.960.0669--25.05--36.80------
Surgical Innovations Group Plc11.92m-1.44m4.20m88.00--0.4903--0.3523-0.0015-0.00150.01280.00920.93142.914.72135,397.70-11.22-7.76-14.17-9.6027.8929.97-12.04-11.660.95248.460.0987---0.57432.16-281.73---8.28--
Cambridge Nutritional Sciences PLC8.06m1.37m4.76m84.003.500.43052.380.59050.00570.00570.03380.04650.61533.593.5795,940.4810.42-3.2211.69-3.6766.4458.8516.94-7.213.79--0.021---14.77-3.23577.44---29.24--
Feedback plc885.62k-7.32m4.89m28.00--0.7925--5.52-0.2618-0.26180.03090.14070.1174--9.8331,629.29-96.97-38.54-105.98-41.6587.9290.05-826.25-435.27----0.00---25.0514.50-121.85---1.14--
Proteome Sciences plc4.53m-3.33m6.05m36.00------1.34-0.0113-0.01130.0153-0.02910.50875.925.75125,750.00-37.44-8.02----17.4345.80-73.60-15.070.0774-2.512.26---2.800.9731-39.42--31.03--
Rua Life Sciences PLC5.17m-850.00k9.00m33.00--1.26--1.74-0.0137-0.01370.08320.11510.54591.186.23---9.18---10.42--77.10---16.82--3.87--0.0995--------------
Genedrive PLC954.00k-5.23m10.81m43.00--4.56--11.33-0.0093-0.00930.00170.00230.1984--1.8022,186.05-108.81-77.52-153.92-106.30-----548.32-1,016.121.64--0.00--90.42-2.0726.06---10.48--
Verici DX PLC1.40m-5.56m10.91m15.00--0.9642--7.81-0.0229-0.02290.00580.00750.2298--1.6777,631.66-91.48---119.40--81.60---398.12------0.102--229.62--32.75------
Cellbxhealth PLC2.62m-15.78m11.96m119.00--0.2897--4.56-0.0489-0.04890.00810.03620.10280.59391.4622,050.42-61.80-41.90-72.78-46.8162.2718.55-601.37-1,051.132.63-470.570.2387--30.92--29.34------
Abingdon Health PLC8.43m-3.42m15.06m121.00--2.19--1.79-0.0176-0.01760.04350.02741.179.713.8769,661.16-47.42-54.04-70.70-85.9144.3230.37-40.51-110.071.58--0.1625--37.399.99-168.69---26.92--
Inspiration Healthcare Group PLC45.20m-11.44m15.24m214.00--0.9312--0.3372-0.1275-0.12750.50380.18261.032.005.91211,215.00-25.96-6.05-33.03-7.4544.3946.62-25.32-7.011.112.420.441--1.6516.56-148.04--39.05--
Data as of Feb 10 2026. Currency figures normalised to Feedback PLC's reporting currency: UK Pound GBX

Institutional shareholders

42.32%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 07 May 20256.93m15.81%
Canaccord Genuity Wealth Ltd.as of 30 Sep 20253.67m8.37%
Premier Fund Managers Ltd.as of 07 May 20253.05m6.97%
Octopus Investments Ltd.as of 22 Dec 20251.68m3.83%
Herald Investment Management Ltd.as of 31 Dec 20241.63m3.73%
Mole Valley Asset Management Ltd.as of 29 Nov 2024754.27k1.72%
Toscafund Asset Management LLPas of 30 Jun 2025575.00k1.31%
Oberon Investments Ltd. (GB Investment Management)as of 30 Jun 2025205.39k0.47%
Foresight Group LLP (Investment Management)as of 30 Sep 202546.51k0.11%
More ▼
Data from 29 Nov 2024 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.